Andrew’s ‘deal sheet’ includes partnerships with AstraZeneca, Ionis Pharmaceuticals, Alexion Pharmaceuticals, and JDRF, the leading global foundation focusing on type 1 diabetes research. His degrees include an Honours BSc. from Western and an MBA from Simon Fraser University. Over the past two decades Andrew has held roles of increasing responsibility as a senior biotechnology executive (including CEO, CFO and VP roles) and a board member. Andrew’s board roles have included the Simon Fraser Beedie School of Business (Dean’s External Advisory Board), and several publicly listed companies. Recognition as a CEO in the biopharmaceutical industry has included a BIOTECanada Gold Leaf Award for Early Stage Company of the Year, Pacific Finalist – Ernst & Young Entrepreneur of the Year (Canada), and the TSX Venture 50 Award (Top Company Technology & Life Sciences). Prior to his operational experiences, Andrew served as Biotechnology Equities Analyst, Goepel Shields & Partners (now Raymond James Canada).